News

Sale of Control – Closing   Montevidéu, November 29th, 2019 – BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33), a leading […]

Grupo Biotoscana announces change in management Montevideo, October 21st, 2019 – BIOTOSCANA INVESTMENTS S.A. today announced the appointment of Mr. […]

Montevideo, Uruguay March 28, 2018. JAVLOR® is indicated in monotherapy for the treatment of adult patients with advanced or metastatic […]

World Pancreatic Cancer Day Demand better. For patients. For survival. Montevideo, Uruguay, November 15, 2018. To honor the World Pancreatic […]

Grupo Biotoscana promove campanha

Myelodysplastic Syndrome World Awareness Day Grupo Biotoscana interviews Dr. Breno Moreno de Gusmão. Montevideo, Uruguay, October 25, 2018. To celebrate […]

Grupo Biotoscana anuncia novas

Grupo Biotoscana participates in the worldwide breast cancer awareness campaign during the month of October.

Grupo Biotoscana announces approval of antifungal CRESEMBA® in Argentina.

13th Cancer de Mama (Breast Cancer) – Gramado Grupo Biotoscana participates in the 2018 edition. Montevideo, Uruguay, September 5, 2018. […]

16th Infocus 2018 The most important Latin American event in Clinical Mycology Montevideo, Uruguay, August 22, 2018. GBT Grupo Biotoscana […]

World Hepatitis Day 2018 The diagnosis and timely treatment of viral hepatitis can save lives. Montevideo, Uruguay, July 27, 2018. […]

Approval of CRESEMBA® and ZEVTERA® in Peru Grupo Biotoscana announces first approval of antifungal CRESEMBA® in Latam and approval of […]

2018 Asco Annual Meeting GBT attended the 2018 ASCO Annual Meeting in Chicago. Montevideo, Uruguay June 6, 2018. Between June […]

Extension of agreement with Gilead Grupo Biotoscana announces new agreement with Gilead for the Andean region. Montevideo, Uruguay May 10, […]

Launch of LENVIMA® in Brazil LENVIMA®’s first steps in the Brazilian market. Montevideo, Uruguay April 23, 2018. From April 19th […]

World hemophilia day 2018 Grupo Biotoscana joins the world hemophilia day campaign. Montevideo, Uruguay April 17, 2018. On World Hemophilia […]

New initiatives for LENVIMA® Grupo Biotoscana announces new initiatives for LENVIMA®. Montevideo, Uruguay March 12, 2018. BIOTOSCANA INVESTMENTS S.A. (“Company” […]

Colombian Congress of Vascular Surgery and Angiology 2018 GBT sponsored the XXII Colombian Congress of Vascular Surgery and Angiology 2018. […]

Launch of ZEVTERA® in Argentina Grupo Biotoscana announces launch of antibiotic ZEVTERA® (ceftobiprole) in Argentina. Montevideo, Uruguay, March 6, 2018. GBT-Grupo […]

Extension of agreement with Biocad Grupo Biotoscana announces extension of agreement with Biocad to include exclusive license for Infliximab in […]

J.P. Morgan Healthcare Conference Between January 8 and 11, GBT attended the J.P. Morgan Healthcare Conference in San Francisco, California. […]

HARVONI® approved in Brazil Grupo Biotoscana expects to introduce the product into the market in 2Q18. Montevideo, Uruguay, December 5, […]

Launch of ABRAXANE® / ABRAXUS® Grupo Biotoscana announces the launched of ABRAXANE® / ABRAXUS® in Brazil and Mexico. Montevideo, Uruguay, […]

Exclusive licensing agreement with Eisai Grupo Biotoscana and EISAI sign exclusive licensing agreement for four novel oncology and neurology products […]